Silexion CEO letter details 2025 progress; Phase 2/3 trial in LAPC set for H1 2026

Silexion Therapeutics Corp

SIL204 showed >90% inhibition in human cancer cell lines across 8 KRAS mutations and 5 tumor types.
Positive regulatory feedback from Germany's BfArM on Phase 2/3 design; toxicology studies completed.
Phase 2/3 LAPC trial initiation planned H1 2026; US IND expected H2 2026.
Company raised over $18M in 2025 and regained Nasdaq compliance; addressable market >$30B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.